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We developed two cancer vaccine platforms in mouse models and 
translated these into human clinical trials with promising preliminary 
results. First, we studied TARP, a prostate cancer antigen discovered 
at NCI [1], mapping HLA-A2-presented epitopes, and testing these 
in HLA-A2-transgenic mice [2]. We then modified the amino acid 
sequences to improve binding to HLA-A2, and tested in mouse mod-
els whether the modified peptides were more immunogenic and 
induced T cells that recognized the unmodified peptide. We call this 
process “epitope enhancement.” We confirmed that the enhanced 
peptides could stimulate human T cells in  vitro to kill human cancer 
cells expressing HLA-A2 and TARP [2]. The mouse studies led to our 
phase I clinical trial in patients with stage D0 prostate cancer, in which 
the primary tumor is removed but a rising PSA indicates microscopic 
recurrence, before any tumor can be seen radiographically. Patients 
were immunized with 2 TARP peptides either in Montanide-ISA51 
or pulsed onto autologous dendritic cells (DCs). Because there was 
no difference in outcomes, we could pool the arms for higher statis-
tical power. At 6  months  >71% of the patients had a decreased rate 
of PSA rise (p = 0.0012), which has been shown to be a valid predic-
tor of outcome. At 1 year, 74% of patients had a decreased PSA slope 
(p =  0.0004). By fitting to an exponential growth curve, the median 
tumor growth rate constant was cut in half [3]. A randomized, placebo-
controlled phase II study is underway with a broader set of TARP pep-
tides to avoid restriction to HLA-A2 patients.
Second, we developed a vaccine targeting the HER2 oncogene, 
responsible for about ¼ of breast cancers and a smaller % of several 
other cancers. For mice, we made an adenovirus expressing the extra-
cellular and transmembrane domains of rodent HER2. In HER2-trans-
genic BALB/c mice that inexorably develop tumors in all 10 mammary 
glands, early vaccination could prevent tumor appearance [4, 5]. In 
wild-type BALB/c mice injected with TUBO tumor cells from the trans-
genic mice, the vaccine cured large (2-cm) established tumors and 
lung metastases [6]. The mechanism, surprisingly, was purely antibody 
mediated, by antibodies inhibiting HER2 phosphorylation, and was 
FcR independent, unlike trastuzumab. We are engaged in a clinical trial 
in patients with advanced metastatic  HER2+ tumors who have failed 
other therapies. Among patients naïve to trastuzumab, in the second 
and third dose cohorts, 5/11 patients had some clinical benefit. Thus, 
two cancer vaccine platforms developed in transgenic mouse models 
were successfully translated to human trials with promising results.
Trial registration
NCI Trials 09-C-0139, 15-C-0075 and 15-C-0076 on TARP prostate can-
cer vaccine
NCI Trial 13-C-0016 on AdHER2 vaccine trial
References
1. Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I. TARP: a nuclear protein 
expressed in prostate and breast cancer cells derived from an alternate 
reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci 
USA. 2000;97:9437–42.
2. Oh S, Terabe M, Pendleton CD, Bhattacharyy A, Bera TK, Epel M, Reiter Y, 
Phillips J, Linehan WM, Kasten-Sportes C, et al. Human CTL to wild type 
and enhanced epitopes of a novel prostate and breast tumor-associated 
protein, TARP, lyse human breast cancer cells. Cancer Res 2004;64:2610–8.
3. Wood LV, Fojo A, Roberson BD, Hughes MSB, Dahut W, Gulley JL, Madan 
RA, Arlen PM, Sabatino M, Stroncek DF, et al. TARP vaccination is associated 
with slowing in PSA velocity and decreasing tumor growth rates in patients 
with stage D0 prostate cancer. Oncol Immunol. 2016:e1197459.
4. Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky 
JA, Morris JC. Vaccination by genetically modified dendritic cells expressing 
a truncated neu oncogene prevents development of breast cancer in 
transgenic mice. Cancer Res. 2004;64:8022–8.
5. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA. 
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus-vaccine 
protection against autochthonous mammary carcinomas. J Immunol. 
2005;174:4228–36.
6. Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC, Berzofsky JA. Therapy 
of advanced established murine breast cancer with a recombinant adeno-
viral ErbB-2/neu vaccine. Cancer Res. 2008;68:1979–87.
A2  
Rat models of susceptibility to complex diseases: a solution 
to Eroom’s Law
Lauren Gerard Koch, Steven L. Britton
Department of Anesthesiology, University of Michigan, Ann Arbor, 
Michigan 48109 USA
Correspondence: Steven L. Britton (britton@umich.edu)  
Journal of Translational Medicine 2017, 15(Suppl 3): A2
A 30 institution consortium seeks a partner to discover effective 
and safe drugs utilizing rat models of multiple complex disease 
conditions that have a common underlying mechanism.
The problem: Between 1950 and the present, the inflation-adjusted 
industrial development costs per drug increased nearly 100-fold 
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Moore’s Law backwards) by Jack Scannell. Eroom’s Law is an enigma 
because huge high-throughput technological gains should have 
raised the efficiency of research and development (R&D). A recent 
quantitative decision-theoretic model [1] of the R&D process led to the 
conclusion that Eroom’s is explained by: (1) limited creation and use of 
valid animal models of disease, and (2) too much reliance on reduc-
tionist molecular approaches that are devoid of the very complex-
ity that embodies emergent disease conditions.
The solution: We foresaw this reductionist dilemma and opted for 
an integrative, theory-based, approach to resolve complex diseases 
[2]. We had noted a clinical literature that strongly linked low exercise 
capacity and high morbidity and mortality. By connecting this clinical 
observation with a theoretical base, we hypothesized that: variation in 
capacity for energy transfer metabolism is the central mechanistic deter-
minant between disease and health (energy transfer hypothesis: ETH). As 
a predictive test of this hypothesis, we show that two-way selective 
breeding of genetically heterogeneous rats for low and high intrinsic 
treadmill running capacity (used as a surrogate for energy transfer) 
also produces rats that differ for disease risks. The lines are termed Low 
Capacity Runners (LCR) and High Capacity Runners (HCR) and after 36 
generations of selection differ by over eightfold in running capacity. 
Consistent with the ETH, the LCR score high for developing numerous 
complex disorders (Table 1).
Table 1 Disease/risks (LCR relative to HCR)




Obesity Spontaneous NAFLD 
inducible into NASH
↑ Susceptibility to 
infectivity
Diabetic neuropathy Alzheimer’s neurode-
generation
↓ Metabolic flexibility
Reduced longevity ↑ Vulnerability to ven-
tricular fibrillation
↑ Inducible cancer
Thus, the LCR and HCR contrast for low health and high health as 
underwritten by the common feature of capacity for energy transfer.
Drug discovery path: A university drug discovery consortium has 
been formed that is comprised of 30 institutions experienced in study 
of the LCR/HCR rats. This consortium seeks to couple with an industrial 
partner and organize to: (1) share all pre-publication outcomes in the 
LCR/HCR rats, (2) make suggestions for needed studies, (3) conduct 
industry in-house study of the rats, and (4) provide new and patented 
agents for testing of efficacy and safety.
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We will present our laboratory’s recent research efforts in rapid contin-
uous projection 3D bioprinting to create 3D scaffolds using a variety 
of biomaterials. These 3D biomaterials are functionalized with precise 
control of micro-architecture, mechanical (e.g., stiffness and Poisson’s 
ratio), chemical, and biological properties [1]. Design, fabrication, and 
experimental results will be discussed. Such functional biomaterials 
allow us to investigate cell-microenvironment interactions at nano- 
and micro-scales in response to integrated physical and chemical stim-
uli. From these fundamental studies we can create both in  vitro and 
in vivo microphysiological systems such as a human liver tissue for tis-
sue regeneration, disease modeling, and drug discovery [2].
To vascularize these engineered tissues, we have developed a prevas-
cularization technique by using the rapid 3D bioprinting method [3]. 
Multiple cell types mimicking the native vascular cell composition 
were encapsulated directly into hydrogels with precisely controlled 
distribution without the need of sacrificial materials or perfusion. 
With regionally controlled biomaterial properties, the endothelial 
cells formed lumen-like structures spontaneously in  vitro. In  vivo 
implantation demonstrated the survival and progressive formation 
of the endothelial network in the prevascularized tissue. Anastomo-
sis between the bioprinted endothelial network and host circulation 
was observed with functional blood vessels featuring red blood cells. 
With the superior bioprinting speed, flexibility and scalability, this new 
prevascularization approach can be broadly applicable to the engi-
neering and translation of various functional tissues.
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Dietary factors are well recognized as major contributors of risk for a 
variety of cardiometabolic conditions, and research in this area utiliz-
ing animal models has long taken advantage of dietary manipulation 
in attempting to induce the desired pathophysiological outcomes. 
Most of the animal-based research related to diet and risk associ-
ated with cardiovascular disease, obesity, and diabetes has, until rela-
tively recently, focused primarily on the impact of specific dietary fats, 
but there is also growing interest in the impact of carbohydrates and 
proteins as well. While the expansion of these efforts to examine the 
impact of these nutritional components has expanded our knowledge 
of cardiometabolic disease risk and progression, the potential contribu-
tion of overall palatability on the feeding behavior of research animals 
has largely been ignored. Data from multiple feeding studies that we 
have conducted in the baboon, a large highly-omnivorous nonhuman 
primate species, suggests the importance of considering palatability 
in the development of dietary challenges to investigate the impact of 
nutritional components on cardiometabolic health. While all animals 
in a controlled research setting must consume the food which they 
are provided, our work indicates that their pattern of consumption, an 
important component in the mechanism of nutritional impact on dis-
ease risk, may vary depending on the palatability of the diet. We have 
found that by increasing the palatability of our challenge diets, simply 
by adding fruit flavoring and baking, we can obtain a pattern of con-
sumption that is most likely more like that seen in humans, and as a 
result more successfully drives the development of the clinical manifes-
tations of interest.
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This abstract is not included here as it has already been published [1].
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Non-alcoholic fatty liver disease (NAFLD) is a rapidly emerging public 
health crisis, affecting up to 1/3 of the U.S. population, 75% of type 2 
diabetics, and 95% of obese individuals, and can progress to non-alco-
holic steatohepatitis (NASH) and cirrhosis, often resulting in liver trans-
plant or death. This is one of the most active areas in drug discovery 
with over 40 drugs in the preclinical and clinical phase of development, 
but none to date advancing beyond Phase III clinical trials or approved 
for therapy. The field is hampered by a lack of disease understanding 
and overreliance on >40 rodent models unable to map to the human 
response. In this presentation, we describe an in  vitro approach that 
combines primary human hepatocytes, stellate cells, macrophages, a 
physiologically relevant tissue microenvironment consisting of liver 
sinusoid hemodynamic and transport conditions, and clinically-derived 
concentrations of NASH risk factors to create “NASH in a dish.” This 
NASH system captures critical pathophysiological drivers of NASH such 
as steatosis, inflammation, and fibrosis and has been validated against 
human NASH biopsy samples [1] and with leading clinical stage drugs. 
To date, we have utilized the in vitro human NASH model to survey the 
current drug development landscape in order to understand the thera-
peutic gaps, providing the principal dataset to identity new targets for 
NASH therapies. This “patient in a dish” concept is also being applied to 
identify novel targets and develop new therapies to treat pediatric rare 
liver diseases [2] and in the future, rare vascular diseases [3].
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Abnormal folding and aggregation of endogenous proteins in the 
brain or peripheral tissues characterizes many degenerative diseases, 
including Alzheimer’s and Parkinson’s disease, amyotrophic lateral 
sclerosis, and type-2 diabetes. The abnormal protein aggregates are 
stable; they can be involved in cell-to-cell propagation of pathology, 
and can adopt conformations with cytotoxic activities. The pres-
ence of plasma antibodies against such misfolded proteins suggests 
active humoral immune responses, along with the formation of B 
cell memory. We hypothesized that selected B cell clones triggered 
by neo-epitopes of pathological protein conformations encode 
antibodies that can block the toxicity and promote the clearance of 
protein aggregates. To test this hypothesis, we analyzed the memory 
B cell repertoires of a large cohort of healthy aged human donors, 
including donors with disease risk and abnormally slow progression 
or onset. Based on these analyses, we generated recombinant high 
affinity human monoclonal antibodies designed to selectively tar-
get pathological neo-epitopes within abnormal protein structures, 
including aggregated Aβ, tau, α-synuclein, TAR DNA-binding pro-
tein 43, superoxide dismutase 1, islet amyloid polypeptide and tran-
sthyretin. These antibodies can be effective in neutralizing toxicity, 
in blocking cell-to-cell propagation, and in triggering the removal of 
protein aggregates by microglia or macrophage-mediated phago-
cytosis. The results of our studies provide the scientific basis for a 
technology in recombinant human monoclonal antibody design, 
resulting in a novel class of efficacious and safe biopharmaceutical 
products. Aducanumab is one such human monoclonal antibody, 
currently in phase III clinical trials for the treatment of Alzheimer’s 
disease. Other candidates are in phase I for Parkinson’s disease and 
tauopathies, and in preclinical stage development for amyotrophic 
lateral sclerosis.
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Tissue health and disease involve complex interactions between the 
microvasculature, stroma and parenchyma of the tissue. The micro-
vasculature itself requires a dynamic interplay between vascular and 
perivascular cell types to maintain proper form and function. With 
this in mind, we developed and implemented a versatile, enabling 
assay platform uniquely positioned to assess an integrated angiogen-
esis response in a complex environment. Involving the use of intact, 
isolated human microvessels in a 3D stromal environment, the assay 
platform recapitulates native angiogenesis for use in phenotypic 
screens of different neovascular behaviors. The system is based on 
bona fide angiogenic sprouting and neovessel growth from isolated, 
intact parent microvessels (e.g., arterioles, capillaries, and venules) 
that retain all intrinsic vascular and perivascular cells within a 3D 
matrix environment. This model system has been effectively used to 
identify and characterize putative angiogenic factors and inhibitors, 
evaluate microvascular instability, and define tissue dynamics during 
angiogenesis. Using the angiogenesis assay, we performed a phe-
notypic screen of a library of 128 compounds targeting a variety of 
epigenetic regulators (primarily histone modifications; Selleckchem, 
Inc.) for their effects on angiogenesis. In the screen, angiogenesis 
was assayed in 3D cultures of isolated microvessels under serum-free 
conditions that modestly promote angiogenesis, enabling us to iden-
tify agents that either stimulate or inhibit angiogenesis. In the assay, 
neovessels sprout from the seeded, whole parent microvessels in a 
regimented fashion resulting in an increase in total vessel length over 
time, measured as fractional microvessel area using the Cytation™ 3 
scanner and Gen5 analysis software (BioTek, Inc.). This vascularizing 
system, based on native microvessels in a 3D environment, is a versa-
tile assay platform, compatible with high-content analysis modalities, 
with proven utility in a variety of research and pharmaceutical appli-
cations. In addition, the microvessels are showing promise in regen-
erative medicine and tissue fabrication as a promising vascularizing 
solution.
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Translational Aspect: Over the past few decades several large-scale 
epidemiological studies show that high performance on tests of 
maximal exercise capacity associates with lower all-cause morbidity 
and mortality. Concomitantly, maintaining an aerobic-based exercise 
program is a primary recommendation for the prevention and treat-
ment of chronic disease, and one of the most important interventions 
for successful aging and longevity. Yet, there is wide inter-individual 
variation for exercise capacity and up to 20% of human subjects are 
considered “exercise resistant”; i.e., demonstrate little or no change in 
maximal oxygen consumption (VO2max) in response to training. The 
goal of our research is to develop contrasting animal model systems to 
systematically translate the clinical observation that variation in exer-
cise capacity is a strong indicator of health and underlies our risk for 
complex disease, accelerated aging, and diminished longevity.
Model Approach: We used large-scale two-way artificial selection 
in genetically heterogeneous rats across several generations to pro-
duce two unique animal models for exploration into wide-ranging 
genomic-environment interactions: One model system differs in 
intrinsic (non-trained) capacity for maximal treadmill running—low 
capacity runners vs. high capacity runners, and a second model differs 
in capacity to respond to treadmill exercise training (acquired)—low 
response trainers vs. high response trainers. We maintain a breeding 
colony consisting of a total of ~50 families as an international research 
resource, retain a detailed 40-generation pedigree database, and 
archive biological tissues samples for molecular tracking purposes.
Results: We found that two-way artificial selective breeding of rats 
for low and high innate exercise capacity is heritable, genetically seg-
regating, and yields rats that differ for numerous disease risks, includ-
ing the metabolic syndrome, Alzheimer’s-like neurodegeneration, 
cognitive decline, susceptibility to inducible breast cancer, premature 
aging, and reduced longevity. Critically, we discovered that maximal 
oxygen consumption (VO2max) was a strong predictor of lifespan. 
Our development of rat models with similar mid-level intrinsic capac-
ity but different magnitude for capacity to gain in response to endur-
ance exercise training affords a unique opportunity to test whether 
attaining a high aerobic capacity/VO2max via training is necessary for 
the beneficial effects of exercise on longevity. The selection criterion 
for this animal model is the change in treadmill running capacity in 
response to 8 weeks of treadmill run training. We found that “exercise 
resistant” rats have low responses to training, especially for VO2max, 
cell remodeling, angiogenesis, mitochondrial expansion, and neuro-
genesis whereas the “exercise sensitive” rats display robust exercise-
induced responses across lifespan, including benefit from late-life 
training.
Conclusions: Exercise intervention is regarded as the first line of 
defense for reducing or ameliorating several complex disease risks. 
Here we show that exercise genomic rat models via selection provide 
unbiased support that variation in exercise capacity (either intrin-
sic or acquired) correctly forecasts future health and disease across 
aging. Moreover, this original and translational animal model system 
represents a basic yet highly individualized underlying process that 
can be probed repeatedly across lifetime for more detailed informa-
tion regarding efficacy and specificity within drug discovery and 
development.
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One important application of animal models is, of course, to identify 
mechanisms through experimental perturbation. A less well-known 
application is to utilize natural variation to study complex interactions. 
Our lab studies a panel of diverse inbred strains of mice to understand 
interactions between genetics, sex, the microbiome, and diet in the 
context of cardiometabolic disease [1].
One surprising finding from our work is that genetic variation of the 
host is a major determinant of the composition of the gut microbiome. 
For example, when our panel of common inbred strains of mice were 
maintained in the same vivarium and fed the same diet, the herit-
ability of gut microbiota was about 40% or higher for most genera of 
gut bacteria [2]. Nevertheless, the microbiome could be dramatically 
altered by dietary challenge (for example, switching from a chow to a 
high fat diet), and microbiota transplantation studies showed that the 
effects of the diets on the host were dependent in part upon the com-
position of the gut microbiota.
We also found that effects of dietary challenge were highly depend-
ent upon genetic background, sex, and microbiome composition [3]. 
This is, of course, consistent with our everyday experience: we all know 
individuals who can eat endlessly but remain lean. While the lessons 
we learn of studies in mice may not be directly translatable to humans, 
an understanding of the basic principles will help guide human 
studies.
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Checkpoint inhibitor therapy is approximating its first horizon that 
encircles a landscape within which cancer cells survive immune 
destruction, thanks to mechanisms that simultaneously dampen its 
effectiveness. Beyond this horizon, a deserted landscape dominates, 
where immune interactions between the host and cancer cells are 
negligible or absent. In this desert, current immunotherapy targets are 
most likely irrelevant.
Available data suggest that three landscapes best portray the cancer 
microenvironment: an immune-active, an opposite immune-deserted 
and an intermediate immune-depleted. This trichotomy is observ-
able across most solid tumors, suggesting that convergent evolution-
ary adaptations determine the survival and growth of cancer in the 
immune competent host.
We refer to the mechanisms allowing persistence of cancer in the 
immune-active cluster as compensatory immune resistance (CIRes). 
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Conversely, we refer to survival of cancer in the immune-silent envi-
ronment as primary immune resistance (PIRes).
To explain CIRes and PIRes, several models have been proposed that 
largely outnumber the fewer immune landscapes. Such discrepancy 
can be explained in three ways: (a) some models do not apply to 
human cancers, (b) there are subtler immune landscapes than those 
discernable by current approaches, or (c) some models describe differ-
ent facets of the same phenomenology.
We previously described a transcriptional signature comprising the 
concordant activation of innate and adaptive immune effector mecha-
nisms required for the occurrence of immune-mediated tissue-specific 
destruction. The latter represents a conserved mechanism determin-
ing destructive autoimmunity, clearance of pathogen-bearing cells, 
acute allograft rejection, graft-versus-host disease, and rejection of 
cancer. Thus, we termed this signature: the Immunologic Constant of 
Rejection (ICR) [1]. We subsequently observed that the ICR serves both 
as positive predictor of responsiveness to immunotherapy, and as 
favorable prognostic marker [2]. This observation suggests that these 
related phenomena represent facets within the continuum of anti-
cancer immune surveillance. Such continuity suggests that signatures 
predictive of prolonged survival may mark an immune-favorable can-
cer phenotype and serve as surrogate predictors of responsiveness to 
anti-cancer immunotherapy when no outcome data are available [3, 
4]. Based on this assumption, we built a navigational map of cancer to 
assign distinct immune-resistance models to the respective immune-
landscape. The survey confirmed that immune suppression strictly 
goes hand-in-hand with immune activation in the favorable land-
scape, while the silent landscape is characterized by lack of immune 
modulation and by a lean oncogenic process that permits growth 
without activation of the host’s defense mechanisms.
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The fatal, primarily childhood, neurodegenerative disorders known 
collectively as neuronal ceroid lipofuscinoses (NCLs), are currently 
associated with mutations in 14 genes. The protein products of these 
genes (CLN1 to CLN14) differ in their function and their intracellular 
localization. NCL-associated proteins have been localized mostly to 
lysosomes (CLN1, CLN2, CLN3, CLN5, CLN7, CLN10, CLN12, and CLN13) 
but also the endoplasmic reticulum (CLN6 and CLN8), or in the cytosol 
associated to vesicular membranes (CLN4 and CLN14). Some of them, 
such as CLN1 (palmitoyl proteinthioesterase 1), CLN2 (tripeptidyl-
peptidase 1), CLN5, CLN10 (cathepsin D), and CLN13 (cathepsin F), are 
soluble lysosomal proteins; others, like CLN3, CLN7, and CLN12, have 
been proposed to be lysosomal transmembrane proteins. Mouse mod-
els for many of these NCLs are available allowing studies of therapeu-
tics that have led to clinical trials. The development of porcine models 
has more recently become important. As our understanding of the 
pathology of these diseases has advanced, identifying the right col-
laborators to execute understanding disease mechanisms, performing 
pre-clinical studies and moving to clinical trials has been important.
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Animal models of central nervous system (CNS) diseases are widely 
used for both basic research and drug development as they provide 
understanding about the underlying disease pathophysiology, symp-
toms, and possible treatment targets that cannot be easily examined 
in human tissues. Despite the benefits and insights that animal mod-
els provide, the emerging view is that animal models of disease are 
limited in their ability to model human disease. Over the past several 
decades, there have been well documented failures in the clinic for 
drugs targeting major neurological diseases. These failures have been, 
at least in part, due to the lack of translational properties of animal 
models including methods that are used to test the efficacy of novel 
drugs. However, advances in new technologies to measure physiologi-
cal and biochemical endpoints have armed the scientific community 
to more accurately and reliably understand the pathophysiology and 
therapeutic response of disease using new and established preclinical 
animal models.
In this presentation, we will go through some examples of established 
animal models of CNS diseases, their key properties, and examine how 
well they model human disease. We will also address issues related to 
interpretations in animal behavior studies and how valid interpreta-
tions mimic human symptoms and behaviors. We will also describe 
novel methods that help us build translational bridges between mice 
and men, in turn, improving our confidence in the preclinical data to 
increase translatability to the clinic. These examples include clinically 
applied imaging techniques, such as positron emission tomography 
(PET), magnetic resonance imaging (MRI), as well as more advanced 
animal behavioral techniques such as touch screen operant assays 
and kinematic motion analysis. We will also present an example of 
how multi-model studies in the rodent brain led to the discovery of 
vascular and metabolic anomalies of the liver, which has serious impli-
cations for biomedical research beyond CNS disease research. This 
finding highlights the importance of understanding animal models 
thoroughly by applying a broad selection of different types of technol-
ogies and approaches. Similar studies will improve our understanding 
of how well animal models represent human disease and help us find 
ways to improve their characteristics to accelerate preclinical CNS dis-
ease drug development.
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Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic 
liver disease and a growing indication for liver transplantation for 
end-stage liver disease as well as liver cancer. There are currently no 
approved therapies for NASH. While a large number of therapeutic 
targets have been identified, it is not clear which targets are relevant 
at which stage of disease. These underscore the need for viable pre-
clinical animal models of NASH that recapitulate all of the stages of 
NASH development and progression, and also recapitulate the human 
disease with respect to inducers, i.e., diet-induced obesity and not a 
specific gene knockout, insulin resistance, dyslipidemia, liver histology 
including the development of hepatocellular ballooning with Mallory 
Denk bodies, activation of pathways known to be relevant to human 
disease, and a transcriptomic profile similar to that in humans. We here 
describe such a model where the phenotype was originally noted in a 
B6129SF2/J (Stock# 101045) mice family and which is now shown to 
meet the above noted criteria in a consistent manner by brother-sister 
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inbreeding to create an isogenic mouse strain (based on Jackson Lab-
oratories SNP panel) which shows it to have about 60% C57 genes 
and 40% S129 genes. Of note, neither parent strain develops the full 
phenotype consistently. Chow-fed mice remain healthy and have a 
normal life span; however, upon high fat diet (42% calories from satu-
rated fat, 0.1% cholesterol) with ad lib glucose fructose in amounts to 
mimic the general macronutrient composition seen in humans with 
NASH, the mice develop obesity, insulin resistance and hypercholes-
terolemia (including LDL-Cholesterol) and triglycerides. After 4 weeks 
of diet, they have profound steatosis, and by 12–14 weeks steatohepa-
titis which is well established by week 16 when early sinusoidal fibrosis 
is noted. This progresses to stage 2 fibrosis by week 24 and bridging 
fibrosis is seen after 36  weeks. The steatohepatitis includes classical 
hepatocellular ballooning with M-D bodies. At week 52, there is florid 
steatohepatitis and bridging with early nodule formation. Hepatic 
adenomas and adenocarcinomas develop in 50–60% of female and 
80–90% of male mice between weeks 36–52, and most mice do 
not survive past week 60. There is activation of lipogenic SREBP-1c 
dependent genes by week 4–6 along with oxidative stress, and ER 
stress developing by week 16. PPAR-α activation occurs in the first 
10 weeks and then declines. There is progressive inflammatory/apop-
totic activation over time, and fibrogenesis from week 16 onwards. 
Gene enrichment analysis indicates that the pathways activated have 
a strong concordance with human NAFLD (FDR 0.01–0.06 at various 
stages). At a transcriptomic level, the gene signature of the tumors 
are similar to those seen in humans with NAFLD and HCC (FDR < 0.01). 
Proof of concept studies with pioglitazone (positive control) have 
been performed to demonstrate the plasticity of the model. These 
mice also develop progressive diastolic dysfunction and diastolic heart 
failure similar to those seen in obese diabetic humans and recently 
reported by us for NASH. Finally, this phenotype has been preserved 
after rederivation of the mice in two separate environments distinct 
from the original environment where they were derived. Together, 
these data indicate that this mouse captures the key elements of 
human disease and provide a tool to better understand the inter-
relationships between pathways with disease progression, and also to 
test the therapeutic potential of individual or combination therapies 
for NAFLD, NASH, NASH with fibrosis, hepatic fibrosis or hepatocellular 
cancer, and even heart failure associated with obesity.
Conflict of interest statement: The mouse model described was vali-
dated at VCU School of Medicine but is now available through a mouse 
CRO Sanyal Biotechnologies of which the author is the President.
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Regenerative medicine is the field of biomedical R&D and clinical prac-
tice focused on repairing, regenerating or replacing tissues and organs 
that have been lost or damaged due to injury, disease and the degen-
erative changes associated with aging. Much of regenerative medi-
cine R&D remains focused on developing stem cell and in vitro tissue 
engineering therapies. Despite over 15 years of extensive research and 
investment, these approaches have not generated viable treatments 
and remain challenged by serious problems with efficacy, by their 
complexity and expense, and by regulatory hurdles.
Discovery and development of small molecules capable of activating 
innate tissue repair and regenerative processes is a newly emerging 
field in regenerative medicine. Small molecules have multiple advan-
tages compared to other regenerative medicine therapeutic strate-
gies, including greatly reduced complexity, likely lower treatment 
costs, reduced regulatory hurdles, ready reversibility of the therapy, 
and lack of ethical concerns. However, small molecule discovery and 
development to date has been constrained by limited understanding 
of the molecular mechanisms underlying regenerative processes.
Arguably, the most economical and efficient strategy for development 
of small molecules with regenerative medicine applications is to use 
“non-traditional” animal models for both target- and phenotype-based 
drug discovery. Countless invertebrate and lower vertebrate animals, 
including Drosophila and zebrafish, exhibit remarkable regenerative 
capabilities. The zebrafish in particular is able to fully regenerate many 
lost or damaged body parts. In contrast, humans and other mammals 
have limited capacity for regenerating damaged tissues, even though 
they possess the genetic instructions needed for building tissues and 
organs de novo during embryogenesis.
Novo Biosciences, Inc. and the MDI Biological Laboratory have under-
taken a focused effort to develop lead small molecules capable 
of activating endogenous tissue regenerative mechanisms. Using 
genome-scale and hypothesis-driven comparative studies of organ-
isms with both robust and limited regenerative capacity, we are iden-
tifying the regulatory gene and signaling circuits and putative drug 
targets that control the regeneration of lost and damaged tissues. 
These efforts are greatly facilitated by RegenDbase, a unique compu-
tational biology and bioinformatics tool we have developed. We also 
use the zebrafish for phenotype-based small molecule screening and 
discovery. I will discuss in detail the discovery and characterization of 
MSI-1436, the first and to date only small molecule capable of induc-
ing regeneration in the adult mammalian heart following ischemic 
injury.
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We have implemented quantitative systems pharmacology (QSP), an 
integrated and iterative computational and experimental approach to 
drug discovery [1], for drug discovery programs in neurodegenerative 
diseases, liver diseases, and metastatic cancers, including metastatic 
breast cancer. We have evolved a human, 3D, 4 cell type, microfluidic, 
liver microphysiology system (MPS) as a key experimental component 
of our metastatic breast cancer and liver disease programs [2, 3, 4]. The 
evolution of the liver MPS has been driven by the following principles: 
(a) recapitulate the liver acinus structure, including zonation, and func-
tion for at least one month; (b) evolve the complexity and functional-
ity on a “fit for purpose” for efficacy testing and ADME-Tox; (c) develop 
and implement iPSC-derived liver cells from patients to capture het-
erogeneity of genomic and disease backgrounds; (d) create and 
implement real-time fluorescence-based biosensors [5], together with 
measurement of drugs, metabolites, and secreted molecules in the 
efflux media; (f ) implement a microphysiology database to manage, 
analyze, and model data [6]; (g) design the liver MPS as a stand-alone 
liver or coupled to other organ MPS such as the intestine and kidney 
[7]; and (h) design should be scalable.
Recent studies have demonstrated the expression of mutations in 
the estrogen receptor alpha (ESR1, ER) from tumors of patients with 
ER+  metastatic breast cancer who had been treated with estrogen-
deprivation therapy. The mutations are concentrated within the ESR1 
ligand-binding domain (LBD), and their development has been dem-
onstrated in 20–50% of ER+ metastatic breast cancer patients in anti-
hormone therapy-resistant metastases.
Metastatic breast cancer involves intravasation, extravasation and 
“seed and soil” growth establishment in the target organ. Our initial 
studies are being investigated in the human liver MPS by exploring the 
seed and soil growth and drug sensitivity using the wild-type estrogen 
receptor alpha (ESR1) and two of the most common mutations, D538G 
and Y537S in comparison to experiments performed in 2D where 
we explored distinguishable phenotypes that these mutations may 
confer using genome-editing methods [8]. We utilized a luciferase-
based assay and an endogenous phospho-ER immunoblot analysis to 
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characterize the estrogen response of ER mutants. Expression of either 
mutant conferred estrogen-independent ER transactivation and ser 
(118) phosphorylation. While ER transactivation and phosphorylation 
in Y537S-expressing clones showed no estrogen dependence, D538G 
mutants demonstrated an enhanced estrogen-dependent response in 
both assays. Additionally, both mutations conferred significant resist-
ance to ER antagonists with Y537S mutants displaying greater resist-
ance than D538G mutants [8]. The same studies are in progress within 
the liver MPS.
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